Oct. 20 at 5:51 PM
$RNXT has FDA cleared RenovoCath already generating revenue, TAMP technology used in solid tumors targets medicine where it needs to be instead of systemic poisoning with ugly side effects. TigerPac pancreatic in phase III, 2 interim look showed a 6 month survival advance, DSMB recommended trial to continue. 65% reduction in Adverse events compared to standard of care.